Journals / Gülhane Tıp Dergisi / 2012 / Cilt: 54 - Sayı: 4

Clinical and laboratory features of progressive supranuclear palsy: Five cases retrospective analysis

Progresif supranükleer palsi'nin klinik ve laboratuar özellikleri: Beş olgu'nun retrospektif analizi

Pages
293–297
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore it is essential to formulate better clinical diagnostic criteria, to permit correct management of the disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Progressive supranuclear palsy (PSP) is a form of neurodegenerative disease which affects the brainstem and basal ganglia.
📊
Key Findings & Data:We analyzed five cases of PSP from 1 January 2005 to 31 December 2009.
💡
Conclusion & Impact:Therefore it is essential to formulate better clinical diagnostic criteria, to permit correct management of the disease.
🔬Design:Research Article
📍Scope:2005 Verileri
⚙️Variables:Domain Parameters

Abstract

Progressive supranuclear palsy (PSP) is a form of neurodegenerative disease which affects the brainstem and basal ganglia. Patients present supranuclear ophthalmoplegia, postural instability and mild dementia. We analyzed five cases of PSP from 1 January 2005 to 31 December 2009. All patients underwent a memory test, autonomic examination, brain magnetic resonance imaging (MRI) and they evaluated by formal neurologic examination. All were taking L-dopa or dopamine agonists. At the onset of PSP the initial diagnosis was Parkinson’s disease in all patients. The brain MRI findings were revealed severe midbrain atrophy, while mini-mental state examination disclosed cognitive impairment, with predominant subcorticalfrontal involvement. Autonomic tests were failure in three of the patients. We emphasize the still obvious current difficulty in diagnosing PSP at an early stage in clinical practice. Therefore it is essential to formulate better clinical diagnostic criteria, to permit correct management of the disease.

Özet

Progresif supranükleer palsi (PSP) beyinsapı ve bazal ganglionları etkileyen nörodejeneratif hastalıkların bir formudur. Hastalar supranükleer oftalmopleji, postural instabilite ve hafif demansla kendini gösterirler. 1 Ocak 2005 ile 31 Aralık 2009 tarihleri arasında PSP’li 5 olguyu inceledik. Hastaların klinik bulguları, demografik bulguları, beyin manyetik rezonans görüntüleme (MRG), bellek testi ve otonomik inceleme sonuçları incelendi. Hastaların tümü L-dopa ya da dopamin agonisti alıyordu. PSP başlangıcındaki ilk tanı tüm hastalarda Parkinson hastalığıydı. Beyin MRG’ de ciddi mezensefalon atrofisi vardı, mini-mental durum muayenesi predominant subkortikal frontal atrofi ile ilişkili kognitif bozulma olduğunu göstermekteydi. Hastaların üçünde otonomik testler bozuktu. Biz klinik pratikte PSP tanısının erken dönemde konulmasının halen zor olduğunu vurgulamak istedik. Buna rağmen daha iyi klinik tanı kriterlerinin ortaya konmasının hastalığın doğru yönetilmesine izin vereceğini düşünmekteyiz.

🔖

Cite This Article

YÜCEL, M., ÖZ, O., AKGÜN, H., ULAŞ, Ü. H., DEMİRKAYA, Ş., KÜTÜKÇÜ, Y., ODABAŞI, Z. (2012). Clinical and laboratory features of progressive supranuclear palsy: Five cases retrospective analysis. Gülhane Tıp Dergisi, Cilt: 54 - Sayı: 4, 293–297. https://ajindex.com/articles/226391

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Burn DJ, Lees AJ. Progressive supranuclear palsy: where are we now? Lancet Neurol. 2002;1(6):359-69 (PMID: 12849397
  2. Litvan I, Agid Y, Calne D. ve ark. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele– Richardson–Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47(1):1-9. (PMID:8710059
  3. Williams DR, Lees AJ Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol. 2009;8(3):270-9 (PMID: 19233037
  4. Golbe LI, Davis PH, Schoenberg BS. ve ark. Prevalence and natural history of progressive supranuclear palsy. Neurology 1988;38(7):1031-4 (PMID:3386818
  5. Dickson D, Rademakers R, Hutton M. Progressive supranuclear palsy: pathology and genetics. Brain Pathol. 2007;17(1):74-82 (PMID:17493041
  6. Hauw J-J, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson Olszewski syndrome (progressive supranuclear palsy). Neurology 1994;44(11):2015-9 (PMID: 7969952
  7. Burçluköse Ö, Özel-Kızıl E.T, Duman B. Psikiyatrik Belirtilerle Seyreden Bir İlerleyici Supranükleer Felç Olgusu. Nöropsikiyatri Arşivi 2007;44:117-9
  8. Nath U, Ben-Shlomo Y, Thomson RG. ve ark. Clinical features and natural history of progressive supranuclearpalsy: A clinical cohort study. Neurology 2003 Mar 25;60(6):910-6 (PMID: 12654952
  9. Nieforth K, Golbe L. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol 1993;16(4):338-46. (PMID: 8374914
  10. Kimber J, Mathias CJ, Lees AJ, ve ark. Physiological, pharmacological and neurohormonal assessment of autonomic function in progressive supranuclear palsy. Brain 2000;123 ( Pt 7):1422-30. (PMID: 10869054
  11. Kikkawa Y, Asahina M, Suzuki A. ve ark. Cutaneous sympathetic function and cardiovascular function in patients with progressive supranuclear palsy and Parkinson’s disease. Parkinsonism Relat Disord 2003;10(2):101-6 (PMID: 14644000
  12. Gutrecht JA. Autonomic cardiovascular reflexes in progressive supranuclear palsy. J Auton Nerv Syst 1992: 1;39(1):29-35 (PMID: 1629523
  13. Holmberg B, Kallio M, Johnels B, Elam M. Cardiovascular reflex testing contributes to clinical evaluation and differential diagnosis of parkinsonian syndromes. Mov Disord 2001;16:217– 225 (PMID: 11295773
  14. Rub U, Del Tredici K, Schultz C, ve ark. Progressive supranuclear palsy: neuronal and glial cytoskeletal pathology in the higher order processing autonomic